A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

NCT00251524 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Bevacizumab, Oxaliplatin, Pemetrexed

Sponsor

Veeda Oncology

Collaborators

[object Object]
[object Object]
[object Object]